Cui Xiangmin 4
4 · Nuvation Bio Inc. · Filed Jun 25, 2024
Insider Transaction Report
Form 4
Cui Xiangmin
Director
Transactions
- Purchase
Class A Common Stock
2024-06-24$2.98/sh+336,874$1,003,885→ 2,175,236 total(indirect: By Decheng Capital Global Healthcare Fund (Master), LP) - Purchase
Class A Common Stock
2024-06-20$2.99/sh+87,715$262,268→ 1,762,951 total(indirect: By Decheng Capital Global Healthcare Fund (Master), LP) - Purchase
Class A Common Stock
2024-06-21$3.00/sh+75,411$226,233→ 1,838,362 total(indirect: By Decheng Capital Global Healthcare Fund (Master), LP)
Holdings
- 314,106(indirect: By Decheng Capital China Life Sciences USD Fund III, L.P.)
Class A Common Stock
- 4,183,002(indirect: By Decheng Anbio Limited)
Class A Common Stock
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.90 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). The Reporting Person is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.99 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.93 to $3.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F5]These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). The Reporting Person is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
- [F6]These securities are owned directly by Decheng Anbio Limited ("SPV"). The Reporting Person is a director of SPV. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.